Subject(s)
ABO Blood-Group System/immunology , Antibodies, Monoclonal , Blood Grouping and Crossmatching , Immunoglobulin M , Isoantibodies , Animals , Antibodies, Monoclonal/immunology , Blood Grouping and Crossmatching/methods , Cost-Benefit Analysis , Evaluation Studies as Topic , Humans , Immunoglobulin M/immunology , Indicators and Reagents , Isoantibodies/immunology , MiceABSTRACT
The proportion of leukocytes removed by a cell processor in the provision of leukocyte-depleted blood was found to be dependent on temperature. If both blood and washing saline were at room temperature, more leukocytes were removed than if either the blood or the saline or both were at 4 degrees C. Room temperature processing provides an optimal product for the recipient who requires leukocyte-depleted blood.
Subject(s)
Cell Separation/instrumentation , Leukocytes/immunology , Temperature , Automation/instrumentation , Humans , Isoantibodies , Leukocyte Count , Sodium Chloride/pharmacology , Transfusion ReactionABSTRACT
A new modification of the microtitre complement fixation test, (CFT), is described for the detection of platelet-bound antibodies (PBA). The test was positive in 12 out of 16 patients, (75%), with active autoimmune thrombocytopenic purpura (AITP). It was negative in four patients who were in remission of AITP when tested, in 10 patients with non-immune thrombocytopenia and in 51 normal blood donors. This is a semi-quantitative method in which suspensions of the patients' own platelets consume complement and therefore prevent the lysis of sensitised sheep red cells (SRBC). Sera from some of these cases were also tested for serum anti-platelet antibody (SPA) and immune complexes. The possible mechanisms and the relevance of positive results are discussed.
Subject(s)
Autoimmune Diseases/physiopathology , Blood Platelets/physiopathology , Complement Fixation Tests/methods , Purpura, Thrombocytopenic/physiopathology , Adenosine Diphosphate/pharmacology , HumansABSTRACT
A monoclonal anti-A antibody has been evaluated and found suitable for use as a potent routine ABO grouping reagent, without the use of additives. The IgM anti-A (MH2/6D4) is secreted into the tissue culture supernatant by a permanent line of cloned cells derived by fusion of anti-A producing spleen cells and a mouse myeloma cell line. This is a cost-effective reagent which should reduce production costs by over 50%. This reagent has the advantages inherent in monoclonal antibodies among them the availability of unlimited quantities of unvarying antibody of known properties.
